Nevada Medicaid and Nevada Check Up News (Third Quarter 2024 Provider Newsletter) [Read]

Attention Behavioral Health Providers: Monthly Behavioral Health Training Assistance (BHTA) Webinar Scheduled [See Web Announcement 2009]

Attention All Providers: Requirements on When to Use the National Provider Identifier (NPI) of an Ordering, Prescribing or Referring (OPR) Provider on Claims [Announcement 850]

If you are a Medicaid provider whose revalidation application has not been processed by your termination due date, you will be ineligible to provide services to any Nevada Medicaid or Nevada Check Up recipients, including both Fee-for-Service and Managed Care Organization (MCO) enrolled recipients. See Web Announcement 1265

Enrollment Termination Frequently Asked Questions (FAQs) [Review]

Notifications

Unwinding COVID-19 Information

Known System Issues-Click HERE

Paper claims are no longer accepted by Nevada Medicaid. Please refer to Web Announcement 1733 and Web Announcement 1829 for additional information.

Top 10 Claim Denial Reasons and Resolutions/Workarounds for November 2024 Professional Claims. See Web Announcement 3509.

Top Enrollment Return Reasons and Resolutions for January 2024 Submissions. See Web Announcement 3350.

Top Prior Authorization Denial Reasons for the Third Quarter of 2024. See Web Announcement 3488.

Attention Providers Using the Authorization Criteria Function: Results that return prior authorization (PA) requirements are accurate. For results that return “There are no records found based on the search criteria,” there may be a PA requirement if limits have been exceeded. To verify PA requirements, please refer to the Medicaid Services Manual (MSM) Chapter for your service type at dhcfp.nv.gov and the Billing Guide for your provider type at www.medicaid.nv.gov.

Scheduled Site Maintenance

During the scheduled site maintenance window the Provider Web Portal will be unavailable. The table below shows the regularly scheduled maintenance window. All times will be in the Pacific time zone.

Monday - Friday
12:00AM - 12:30AM

Monday
8:00PM - 12:00AM

Notice Date Title
Dec. 18, 2013 For Review at January 23 Meeting: Botulinum Toxins
Dec. 18, 2013 For Review at January 23 Meeting: Duexis® (Ibuprofen/Famotidine)
Dec. 18, 2013 For Review at January 23 Meeting: Epinephrine for Anaphylaxis Agents
Dec. 18, 2013 For Review at January 23 Meeting: Homozygous Familial Hypercholesterolemia Agents
Dec. 18, 2013 For Review at January 23 Meeting: Immunomodulators
Dec. 18, 2013 For Review at January 23 Meeting: Long-Acting Opioids
Dec. 18, 2013 For Review at January 23 Meeting: Platelet Inhibitors
Dec. 18, 2013 For Review at January 23 Meeting: Short-Acting Opioids
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Antivirals: Influenza
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Botulinum Toxins
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Buprenorphine Products
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Colony Stimulating Factors
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria Cymbalta®
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Fentanyl Immediate Release
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Growth Hormones
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Hereditary Angioedema Agents
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Lomitapide and Mipomersen
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Oral Anticoagulants
July 22, 2013 For Review at July 25 Meeting: Proposed Criteria for Potassium Channel Blockers
June 19, 2013 For Review at July 25 Meeting: Antivirals: Influenza
June 19, 2013 For Review at July 25 Meeting: Growth Hormone
June 19, 2013 For Review at July 25 Meeting: Lomitapide (Juxtapid®)
June 19, 2013 For Review at July 25 Meeting: Mipomersen (Kynamro®)
March 19, 2013 For Review at April 25 Meeting: Botulinum Toxins
March 19, 2013 For Review at April 25 Meeting: Buprenorphine Products
March 19, 2013 For Review at April 25 Meeting: Fentanyl IR Products
March 19, 2013 For Review at April 25 Meeting: Oral Anticoagulants

Return to Past Meeting Materials.